US FDA Nominee Makes A Good First Impression, But This Is Still An Odd Transition
Executive Summary
Stephen Hahn mostly coasted through a confirmation hearing to be the next FDA commissioner – but he still didn’t really give any indication of why he wants the job.
You may also be interested in...
Playing It Safe? Hahn's Biosimilar View
US FDA Commissioner nominee gave a general, scripted answer to a question about biologic patents, but did Stephen Hahn inadvertently go against the agency's stance on the issue?
Hahn Confirmation Hearing: Solid Performance Light On Substance
US FDA commissioner nominee Stephen Hahn does not offer much detail on his policy positions; Senate confirmation could be completed by the end of the year.
Medicare Reaffirms Faith In Formulary Review Process Ahead Of Part D Changes
Dramatic transformation in the US Medicare Part D benefit design does not require any changes to CMS’ overall approach to reviewing formulary submissions from private drug plan sponsors, the agency says in its final guidance implementing the design changes for 2025.